Multiple Myeloma
Key Points
Key Points
The estimated number of deaths from multiple myeloma in 2018 is 12,770, representing 2.1% of all cancer deaths.
Despite significant advances and improvements in overall survival, multiple myeloma remains incurable and additional treatments are needed.
The median survival is just over 5 years and most patients receive 4 or more different lines of therapy throughout their disease course.
Treatment
...Treatment...
...Tra...
...s should be referred to a transplant center t...
...nologic age and renal function should not be the...
...regimen and number of cycles remain unp...
...nsplant should be offered to all transplant-elig...
...ents associated with stem cell toxicity,...
...l collection (sufficient for more tha...
...inimal response required to proceed t...
...-dose melphalan is the recommended conditioning...
...utologous SCT should not be routinely recomm...
Salvage or delayed SCT may be used as consolidati...
...geneic transplant for multiple myeloma is not rout...
...idation therapy is not routinely recommended...
...mide maintenance therapy should be...
...r patients intolerant of or unable to receive...
...high-risk patients, maintenance therapy with a pr...
...s insufficient evidence to make modifications...
...he quality and depth of response should be as...
...of initial therapy for transplant elig...
...recommended that depth of response be assessed...
...dose CT scan has been shown to be superior to ske...
...Transplant In...
...l treatment recommendations for patie...
...treatment for patients with multiple...
...rapies for patients with multiple myeloma who...
.../patients should balance the poten...
...therapy should be offered over fixed d...
...of initial therapy for transplant ineligible patie...
...of response for all patients should be assessed b...
...icient evidence to support change in type and leng...
Upon initiation of therapy, one should def...
...d that patients be monitored closely with consi...
...Relapsed Disease...
...t for biochemically relapsed myeloma sho...
...lly relapsed patients with symptom...
...plet therapy should be administered on first rela...
...t of relapsed multiple myeloma may be conti...
...herapies should be taken into consi...
...utologous stem cell transplantatio...
...of the patients should be assessed using the Rev...
...k assessment at the time of relapse should be p...
...nt of other risk factors such as renal ins...
...tients with genetic high-risk disease a trip...
...n patients with renal insufficiency, dru...
...nts with plasma cell leukemia or extra medullary...
...e IMWG revised response criteria s...
...surable parameters need to be followed including...
...ll responses excluding marrow and imag...
...sment should be performed after one cycle of...
...e 1. Algorithm On Management of Pa...
...Used in the Management of Patients With Multiple...
...nostic Criteria for Active Multiple Myelom...
...sed International Staging System (R...
...4. Comparison of Select Risk Prediction Mode...
...G Response CriteriaHaving trouble viewing...
Table 6. Estimated Cost of Drugs for Multiple Myel...